Patents by Inventor Jeffrey Karpen

Jeffrey Karpen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9458102
    Abstract: Disclosed herein are derivatives of tetracaine that, among other things, block cyclic nucleotide gated (CNG) channels and are useful in the treatment of diseases characterized by overactive CNG channels such as retinal degeneration diseases.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: October 4, 2016
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Jeffrey Karpen, Sarah Kirk, Adriana Andrade, Michelle Schaffer, Kenneth Melich
  • Publication number: 20140018422
    Abstract: Disclosed herein are derivatives of tetracaine that, among other things, block cyclic nucleotide gated (CNG) channels and are useful in the treatment of diseases characterized by overactive CNG channels such as retinal degeneration diseases.
    Type: Application
    Filed: December 14, 2012
    Publication date: January 16, 2014
    Inventors: Jeffrey Karpen, Sarah Kirk, Adriana Andrade, Michelle Schaffer, Kenneth Melich
  • Publication number: 20070099226
    Abstract: The present invention provides modified cyclic nucleotide gated (CNG) channels. In particularly preferred embodiments, the modified CNG channels exhibit increased sensitivity and specificity for cAMP, as compared to wild-type CNG channels. In additional embodiments, regulation by Ca2+-calmodulin has been removed in the modified CNG channels. Convenient optical methods for detecting changes in cAMP, taking advantage of the Ca2+ permeability of the channel are also provided by the present invention. In addition, electrophysiological methods are further provided.
    Type: Application
    Filed: November 16, 2006
    Publication date: May 3, 2007
    Applicant: The Regents of the University of Colorado, a body corporate
    Inventors: Jeffrey Karpen, Thomas Rich, Dermot Cooper, Jerome Schaack, Kent Fagan